Evidence map›Paper›PMID 33375607›Full record

ArticlePharmaceutics2020

Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies.

Wafaa Alabsi, Fahad A Al-Obeidi, Robin Polt, Heidi M Mansour

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wafaa AlabsiDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Fahad A Al-ObeidiDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.
Robin PoltDepartment of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0003-0756-3183
Heidi M MansourCollege of Pharmacy, Skaggs Pharmaceutical Sciences Center, The University of Arizona, Tucson, AZ 85721, USA.
University of Arizona · US

Funding

Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2011 to 2020
$26.8M
Perinatal NO signaling in congenital heart diseaseR01HL137282 · NHLBI · UNIVERSITY OF ARIZONA · PI BLACK, STEPHEN M, FINEMAN, JEFFREY R · 2017 to 2020
$2.7M
Surfactant Protein A as a Novel Therapeutic for AsthmaR21AI135935 · NIAID · UNIVERSITY OF ARIZONA · PI LEDFORD, JULIE GUNNELLS, MANSOUR, HEIDI M. · 2018 to 2019
$422k
Preclinical development of a novel Nrf2-activator formulation for the treatment of idiopathic pulmonary fibrosisR21AG054766 · NIA · UNIVERSITY OF ARIZONA · PI HECKER, LOUISE, MANSOUR, HEIDI M. · 2017 to 2018
$415k
NASA #NNX12AL47G, #NNX15AJ22G,#NNX07AI520NHLBI NIH HHS R01 HL137282NIAID NIH HHS R21 AI135935NIH HHS 5UG3DA047717NIH HHS P01HL103453NIH HHS R01HL137282NIH HHS R21AG054766NIH HHS R21AI135935NSF #1531243 and #EAR-0841669Space Exploration & Optical Solutions (SEOS) TRIF Equipment Enhancement Fund grant award FY2018
6 · The paper itself

Abstract

The purpose of this study was to formulate Lactomorphin (MMP2200) in its pure state as spray-dried(SD) powders, and with the excipient Trehalose as co-spray-dried(co-SD) powders; for intranasal and deep lung administration with Dry Powder Inhalers (DPI). Lactomorphin is a glycopeptide which was developed for the control of moderate to severe pain. Particles were rationally designed and produced by advanced spray drying particle engineering in a closed mode from a dilute organic solution. Comprehensive physicochemical characterization using different analytical techniques was carried out to analyze the particle size, particle morphology, particle surface morphology, solid-state transitions, crystallinity/non-crystallinity, and residual water content. The particle chemical composition was confirmed using attenuated total reflectance-Fourier-transform infrared (ATR-FTIR), and Confocal Raman Microscopy (CRM) confirmed the particles' chemical homogeneity. The solubility and Partition coefficient (LogP) of Lactomorphin were determined by the analytical and computational methodology and revealed the hydrophilicity of Lactomorphin. A thermal degradation study was performed by exposing samples of solid-state Lactomorphin to a high temperature (62 °C) combined with zero relative humidity (RH) and to a high temperature (62 °C) combined with a high RH (75%) to evaluate the stability of Lactomorphin under these two different conditions. The solid-state processed particles exhibited excellent aerosol dispersion performance with an FDA-approved human DPI device to reach lower airways. The cell viability resazurin assay showed that Lactomorphin is safe up to 1000 μg/mL on nasal epithelium cells, lung cells, endothelial, and astrocyte brain cells.

Indexed as

brainCNS therapeuticsdry powder inhalers (DPIs)glycopeptideshuman cellsintranasal deliveryLogPmicroscopymodelingpulmonary delivery

Identifiers

PMID33375607
PMCPMC7824383
OpenAlexW3117695877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.